Clinical Trials

230 enrolled

Phase 1 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04279847 2026-02-25

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05936359 2026-02-10

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

225 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05088356 2025-12-19

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

MyeloidOther hematologic neoplasm

60 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2 Active not recruiting

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT06291987 2025-11-05

MPN

18 enrolled

Myeloproliferative Disorders

NCT00726232 2025-10-29

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase 2 Terminated

73 enrolled 25 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Myeloproliferative Disorders

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT01787487 2025-10-09

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2 Active not recruiting

121 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

MyeloidOther hematologic neoplasmOther neoplasm

336 enrolled

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04562389 2025-10-03

SENTRY

Phase 3 Active not recruiting

353 enrolled

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03878199 2025-09-15

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

12 enrolled

Phase 1 Active not recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT06477549 2024-06-27

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Phase 2 Recruiting

220 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase 2 Completed

23 enrolled 31 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase 2 Terminated

12 enrolled 15 charts

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

50 enrolled 23 charts

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT01348490 2020-01-28

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Phase 2 Completed

66 enrolled 18 charts

Myeloproliferative Disorders

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02076191 2019-02-28

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

49 enrolled

Myeloproliferative Disorders

NCT00952289 2018-03-12

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Phase 3 Completed

309 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01164163 2014-10-23

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Phase 1 Completed

49 enrolled

Myeloproliferative Syndrome, Transient, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01340651 2014-03-10

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase 2 Completed

41 enrolled 15 charts